EW Stock Analysis — Edwards Lifesciences
Sector: Healthcare
AI Verdict
Edwards trades at 27.6x next year's earnings with 60.4% EPS growth expected—cheap for the growth you're getting if its regulatory and hospital lock-in holds, but any stumble could trigger a sharp rerating.
Competitive Moat
Edwards Lifesciences dominates in transcatheter heart valve therapies, protected by decades of clinical data, FDA approvals, and entrenched relationships with cardiac surgeons and hospitals. Its defensibility comes from high regulatory barriers and a specialized salesforce that makes switching costly for hospitals.
Summary
Analysts expect Edwards Lifesciences to grow earnings by 60.4% next year, a sharp acceleration for a medtech company.
Where It Stands
Shares returned 10.87% over the past year, RSI is neutral at 60.8, and the stock trades at 27.6x forward earnings versus a healthcare median of 22x.
Key Metrics
- RSI: 60.8 — Near Overbought
- Trailing P/E: 44.3x
- Forward P/E: 27.6x
- PEG Ratio: 0.73
- Earnings Growth: +0.6%
- Revenue Growth: +0.1%
- Market Cap: $48.0B
- 1-Year Return: 10.87%
- 52-Week High: $87.89
- 52-Week Low: $72.30
Analyst Consensus
32 Buy · 11 Hold · 0 Sell (43 analysts)
Bull Case
With forward EPS growth expected at 60.4% and a PEG ratio of 0.73, the market is offering high growth at a reasonable multiple for a company with entrenched hospital relationships.
Bear Case
If the P/E reverts to the sector median of 22x, that would mean a 20%+ valuation drop even if growth delivers, especially with RSI at 60.8 signaling no margin of safety.
Catalyst to Watch
Watch for upcoming FDA approvals or clinical trial readouts, as positive results could reinforce the moat and justify the premium multiple.